Subcutaneous trastuzumab (herceptin) vs intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit
European Journal of Obstetrics & Gynecology and Reproductive Biology | Dec 12, 2017
Most read this week